# US 2017/0281670 A1 · Redox signaling gel formulation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2017/0281670 A1 - Document ID: US20170281670A1 - Status: Published application - Kind: A1 - Application number: 15/463,925 - Filed: 2017-03-20 - Published: 2017-10-05 - Earliest claimed: 2013-10-24 - Assignees: Reoxcyn Discoveries Group, Inc. - Applicants: Reoxcyn Discoveries Group, Inc. - Inventors: Andrew Hoover - Web page: https://patentgrep.com/patent/US20170281670A1 ## CPC - A61K 31/78: of acrylic acid or derivatives thereof - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 33/00: Medicinal preparations containing inorganic active ingredients - A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} - A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides - A61K 33/40: Peroxides - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/02: Inorganic compounds - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - C25B 1/30: Peroxides - C25B 3/00: Electrolytic production of organic compounds - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C25B: ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR (anodic or cathodic protection C23F13/00; single-crystal growth C30B) ## Abstract Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C. ## Claims ### Claim 1 A stable hydrogel formulation comprising: a reactive oxygen species (ROS); saline; and a rheology modifier. ### Claim 2 (depends on 1) The stable hydrogel formulation of claim 1, wherein the ROS comprises superoxide, hypochlorite, hypochlorate, oxygen derivatives, hydrogen derivatives, hydrogen peroxide, or hydroxyl radicals. ### Claim 3 (depends on 1) The stable hydrogel formulation of claim 1, wherein the rheology modifier comprises a metal silicate gelling agent. ### Claim 4 (depends on 1) The stable hydrogel formulation of claim 1, wherein the rheology modifier comprises SiO2, MgO, Li2O, Na2O, or combinations thereof. ### Claim 5 (depends on 1) The stable hydrogel formulation of claim 1, wherein the rheology modifier comprises a cross-linked acrylic acid polymer. ### Claim 6 (depends on 1) The stable hydrogel formulation of claim 1, wherein the formulation has a pH between about 5 and about 9. ### Claim 7 (depends on 1) The stable hydrogel formulation of claim 1, wherein the formulation is formulated for topical administration to a user. ### Claim 8 A stable hydrogel formulation comprising: sodium present at a concentration of about 1000 to about 2500 ppm; chloride present at a concentration from about 1200 to about 5300 ppm; hypochlorous acid present at a concentration of about 16 to about 67 ppm; superoxide radical present at a concentration of about 94 μM; hydroxyl radical present at a concentration of about 241 μM; and a rheology modifier present in an amount of about 0.1% to about 10% by weight. ### Claim 9 (depends on 8) The stable hydrogel formulation of claim 8, wherein the composition has a pH between about 6 and about 9. ### Claim 10 (depends on 8) The stable hydrogel formulation of claim 8, wherein the sodium, chloride, hypochlorous acid, superoxide radical and hydroxyl radical are measured less than one year after the composition was made. ### Claim 11 (depends on 8) The formulation of claim 8, wherein the formulation is formulated for topical administration to a user. ### Claim 12 (depends on 8) The formulation of claim 8, wherein the formulation has an electron paramagnetic resonance (EPR) spectrum as shown in FIG. 13. ### Claim 13 (canceled) ### Claim 14 (depends on 8) The formulation of claim 8, wherein the rheology modifier comprises a metal silicate gelling agent, SiO2, MgO, Li2O, Na2O, a cross-linked acrylic acid polymer, poly(acrylic acid), or combinations thereof. ### Claim 15 (depends on 1) The stable hydrogel formulation of claim 1, wherein the formulation is stable for at least one year. ### Claim 16 (depends on 1) The stable hydrogel formulation of claim 1, wherein the ROS is present in an amount of greater than about 98% relative to an initial concentration of ROS for at least one year. ### Claim 17 (depends on 1) The stable hydrogel formulation of claim 1, wherein the rheology agent is present in an amount of about 0.1% to about 10% by weight. ### Claim 18 (depends on 1) The stable hydrogel formulation of claim 1, wherein the saline comprises sodium chloride present in an amount of about 0.1% to about 1.0% by weight. ### Claim 19 (depends on 1) The stable hydrogel formulation of claim 1, further comprising a buffering agent, wherein the buffering agent comprises sodium phosphate monobasic. ### Claim 20 (depends on 8) The stable hydrogel formulation of claim 8, wherein the formulation is stable for at least one year. ### Claim 21 (depends on 8) The stable hydrogel formulation of claim 8, wherein the ROS is present in an amount of greater than about 98% relative to an initial concentration of ROS for at least one year.